Introduction
The significance of endothelial dysfunction in cardiovascular disease is well established (Widlansky et al. 2003) . In the healthy state, the endothelium produces a number of factors including nitric oxide that are essential for maintaining vascular homeostasis. Systemic risk factors damage endothelial cells lowering nitric oxide (NO) bioavailability. Endothelial dysfunction facilitates atherogenesis by promoting inflammation, thrombosis and cellular adhesion. Recent studies demonstrate higher risk of cardiovascular events in individuals with impaired endothelial function (Yeboah et al. 2007) .
Since the initial identification of NO, several techniques have been employed to investigate endothelial vasomotor function in humans (McMackin and Vita 2005) . Endothelial function assessment has not yet been incorporated into routine risk stratification in part owing to technical and logistical limitations. The use of a novel digital pulse amplitude tonometry (PAT) device to measure endothelial function offers the possibility of an easily performed, rapid assessment of vascular function (Celermajer 2008) . The current article reviews the use of digital PAT as an indicator of endothelial function.
Testing of Endothelial Function in Cardiovascular Disease
Endothelial health can be assessed by measuring vasodilator responses to interventions known to stimulate endothelial release of NO. Endothelial function testing has many potential applications in both research and clinical practice that are outlined in Table 1 . Several methodologies have been developed to measure endothelial vasomotor function in humans, and these have been the subject of recent reviews (Barac et al. 2007 , Deanfield et al. 2007 , McMackin and Vita 2005 .
The most frequently employed noninvasive endothelial function test is flowmediated vasodilation of the brachial artery assessed with ultrasound. Brachial artery flow-mediated vasodilation is lower in the presence of traditional risk factors and importantly predicts risk for cardiovascular events (Widlansky et al. 2003 , Yeboah et al. 2007 ). Several limitations have precluded the clinical adoption of brachial ultrasound based testing of endothelial function. In particular, the accurate measurement of brachial flow-mediated vasodilation requires extensive sonographer training, expensive equipment, and labor intensive image analysis. In response to these limitations, investigators have developed new methodologies designed to be simple to perform. The ideal test for endothelial function would satisfy a number of important criteria as outlined in Table 1 .
Measurement of Endothelial Function with the Use of Digital PAT
Emerging evidence supports the assessment of digital PAT as a measure of endothelial function. Assessment of vascular function with PAT involves measuring pulse amplitude in the fingertip at rest and following the induction of reactive hyperemia. The EndoPAT device (Itamar Medical, Caesarea, Israel) is a Federal Drug Administration-approved, commercially available system, consisting of a fingertip plethysmograph capable of sensing volume changes in the digit with each arterial pulsation. The device used to measure digital vascular function is shown in Figure 1 . The fingertip probe has a rigid external casing containing inflatable chambers. The uniform applied pressure field across the finger prevents venous pooling and partially unloads arterial wall tension. Volume changes in the fingertip are recorded digitally as pulse amplitude that can be tracked over time.
A complete digital PAT endothelial function test includes three phases: baseline, occlusion, and hyperemia. A PAT probe is positioned on one finger of each hand and set by the computer to inflate to 10 mm Hg below diastolic pressure or 70 mm Hg (the lower value is selected). Recordings are taken simultaneously from both fingers throughout the study. The response in the control finger not experiencing hyperemia can be used to adjust for systemic effects. After baseline data acquisition, a blood pressure cuff is inflated on one arm to suprasystolic pressures for 5 minutes. During the occlusion period, signals are absent from the hyperemic finger but continue from the control finger. After cuff release, pulse amplitude increases in the hyperemic finger. The pulse amplitude recordings are digitized and analyzed by an automated, proprietary algorithm. Average pulse amplitude is calculated for each 30-second intervals after cuff occlusion for up to 5 minutes. The baseline pulse amplitude also is measured and reported in standardized, arbitrary units. The automated assessment of vascular function with PAT produces reliable results. In more than 2,000 eligible participants in the Framingham Heart Study, the rate of technically interpretable studies was over 90% (Hamburg et al. 2008) . The major reasons for technical inadequacy were incomplete cuff occlusion (3%), noisy signal quality (3%) and incomplete data acquisition (3%). A few patient-specific factors limit test performance, including Raynaud's disease, a finger size that does not match the fingertip probe, and a very long fingernail. Owing to computerized analysis approach, interobserver measurement variability is minimized. The published data regarding the reproducibility of the digital vascular responses over time are limited. In two small studies of healthy adults, there was evidence supporting the reproducibility of the PAT hyperemic ratio measured on two days (Bonetti et al. 2003 , Tomfohr et al. 2008 . In 44 children with diabetes, the mean coefficient of variation for the PAT hyperemic response measured 4 weeks apart was 14.8 % (Haller et al. 2007) .
We recently reported the characteristics of the PAT hyperemic response in participants in the Third Generation cohort of the Framingham Heart Study (Hamburg et al. 2008 ). In the hyperemic finger, there was a time-dependent rise in pulse amplitude that on average peaked at 60 to 120 seconds following cuff release. Notably, pulse amplitude increased modestly in the control finger, indicative of a systemic response to cuff occlusion. Owing to the presence of a systemic effect, a measure of the PAT hyperemic response was developed that incorporated the observed changes in the control finger. The PAT ratio was calculated in three steps. First, the ratio of the pulse amplitude in each 30- The thimble-like PAT device is placed on a finger from each hand. Tubing connects the device to a recording unit that transmits data directly to a computer. (Right) The device contains air-filled chambers that are inflated to approximate diastolic pressure throughout the study. Sensors allow detection of changes in finger volume with each arterial pulsation. (Bottom left) A typical setup for a research study is shown. The hand is elevated to allow the fingers to hang freely without touching any surfaces. A cuff is placed on one forearm that will be inflated to suprasystolic pressures to induce hyperemia.
second interval following cuff release to the baseline pulse amplitude was calculated for the hyperemic finger. Second, this ratio in the hyperemic finger was divided by the corresponding ratio in the control finger. Third, because the PAT ratio was not normally distributed and the error structure was heteroscedastic, we performed a natural logarithm transformation to arrive at the final PAT ratio. The PAT ratio can be derived for each 30 seconds interval following cuff release. The portion of the PAT hyperemic response shown to be dependent on endothelial NO release occurs from 60 to 120 seconds following cuff deflation (Nohria et al. 2006) . Notably, the relation between cardiovascular risk factors and the PAT hyperemic response was maximized in the 90-to 120-second time interval (Hamburg et al. 2008) . These findings support selecting the PAT hyperemic response recorded between one and 2 minutes after cuff deflation as the appropriate measure of digital vascular function.
The augmentation of pulse amplitude with hyperemia reflects a complex vascular response to ischemia in the digit (Mitchell et al. 2004) . As the PAT device records pulse amplitude in the finger, changes in the PAT signal reflect, in part, vasodilator function of the digital microcirculation. Importantly, NO production by the endothelium has been shown to contribute to the PAT hyperemic response. In healthy volunteers, infusion of an endothelial NO synthase (eNOS) inhibitor blunted the rise in pulse amplitude measured in the minute following cuff release (Nohria et al. 2006 ). These findings suggest that the increase in digital pulse amplitude that occurs with hyperemia is dependent in part on flow-mediated release of NO and support the use of the PAT hyperemic response as a measure of endothelial function.
Clinical Studies Measuring Endothelial Function with Digital PAT
Investigators have developed evidence supporting the clinical relevance of the PAT hyperemic response. Selected studies measuring PAT hyperemic responses are summarized in Table 2 . Multiple studies have examined the relation of PAT hyperemia to established measures of endothelial function. In addition, studies have examined the associations between traditional and novel cardiovascular risk factors and digital vascular function. Finally, investigators have measured the changes in the PAT hyperemic response after short-term interventions.
Several studies have investigated the relation between vascular function in the digit and other regions. In patients undergoing coronary angiography, lower PAT hyperemic response was associated with the presence of coronary endothelial dysfunction measured by acetylcholine response (Bonetti et al. 2004) . Two studies reported a modest relation between PAT hyperemic response and brachial flowmediated dilation (Dhindsa et al. 2008 , Kuvin et al. 2003 ). Thus, in small studies, digital vascular function appears to be associated with endothelial function in the brachial artery. However, the PAT hyperemic response largely reflects vasodilator responses in digital microvessels, whereas brachial artery flow-mediated dilation measures conduit artery vasodilation. Microvascular function as assessed by PAT has the potential to evaluate a distinct vascular response from conduit vessel flow-mediated dilation.
Several studies have examined the relation of clinical cardiovascular risk factors with the PAT hyperemic response. Kuvin et al. (2003) reported that the PAT hyperemic ratio was progressively lower with increasing burden of cardiovascular risk factors. In patients without obstructive coronary artery disease undergoing coronary angiography, increasing body mass index and decreasing high-density lipoprotein (HDL) were associated with lower PAT hyperemic response in unadjusted analyses (Bonetti et al. 2004 ). Adolescents with type 1 diabetes mellitus also had lower hyperemic PAT responses compared to their healthy peers (Haller et al. 2007 , Mahmud et al. 2008 .
Several emerging cardiovascular risk factors have been linked to impaired Figure 2 . As shown, the tracings on the left are from an individual with a high PAT hyperemic response whereas the tracings on the right are from an individual with a low PAT hyperemic response. The study has three phases. Phase 1 records the baseline pulse amplitude from the probes on both fingers. Phase 2 is during the cuff inflation on one arm. In the test finger flow is occluded but continues in the control finger. Phase 3 is recorded after cuff release. In the test finger, pulse amplitude rises rapidly in the healthy individual but not in the patient with coronary artery disease. In the control finger, flow there is minimal change in pulse amplitude after cuff release. digital vascular responses in small studies. Polycystic ovarian syndrome, preeclampsia, obstructive sleep apnea, acute malaria infection, depression, mental stress, and postprandial hyperglycemia have all been associated with decreased PAT hyperemic response (Crandall et al. 2009 , Itzhaki et al. 2005 , Lowenstein et al. 2007 , Tomfohr et al. 2008 , Yeo et al. 2007 , Yinon et al. 2006 . These studies provide evidence that systemic states associated with cardiovascular risk impair microvessel vasodilator function in the fingertip reflected in lower PAT hyperemic responses.
We examined how cardiovascular risk factors relate to PAT measures in the Framingham Heart Study Third Generation cohort. In this large, communitybased cohort, we reported that cardiovascular risk factors explained close to 16% of the variability in the PAT hyperemic response (Hamburg et al. 2008) . Several cardiovascular risk factors, including male sex, body mass index, total to HDL cholesterol ratio, diabetes mellitus, smoking, and lipid-lowering treatment were all associated with lower PAT hyperemic response. Surprisingly, increasing age was associated with higher PAT hyperemic response. The unanticipated positive association between advancing age and PAT requires further investigation in cohorts with a wider age range and potentially reflects differential aging responses in the digital vessels. Systolic blood pressure and C-reactive protein were not associated with PAT hyperemic response in multivariable models.
We also reported significant relations between cardiovascular risk factors and higher baseline pulse amplitude. Baseline pulse amplitude reflects blood flow, tone, and compliance and may be an important indicator of microvessel structure and function. Overall, these findings suggest that early vascular abnormalities associated with systemic cardiovascular risk factors are reflected in digital vascular responses.
The presence of clinical cardiovascular disease is associated with impaired digital vascular function. Individuals with a stress test with evidence of ischemia had lower PAT hyperemic responses than those individuals without ischemia (Kuvin et al. 2003) . In an ambulatory setting, patients with coronary artery disease had lower PAT hyperemic responses than individuals without established coronary disease (Kuvin et al. 2007) .
Although cross-sectional studies including large numbers of participants have excellent ability to adjust for potential confounding, they cannot establish the temporal relations between risk factors and PAT. Additional evidence for the utility of the PAT hyperemic response is provided by studies showing that shortterm interventions of potential beneficial for vascular health improve the PAT hyperemic response. In patients with refractory angina, enhanced external counterpulsation therapy resulted in higher PAT hyperemic responses and a parallel reduction in anginal symptoms (Bonetti et al. 2003) . Flavonoid-containing supplements improved the PAT hyperemic response (Barringer et al. 2008 , Fisher et al. 2003 , Schroeter et al. 2006 . Several additional therapies, including L-arginine infusion, sildenafil, air filtration to reduce particulate matter, treatment of malaria, and therapy for PAT hyperemic response increased after treatment Nohria et al (2006) 19 healthy subjects Administration of inhibitor of eNOS inhibitor, L-NAME PAT hyperemic response lower after L-NAME consistent with nitric oxide dependence Schroeter et al (2006) 12 healthy subjects Ingestion of flavanol-rich cocoa or epicatechin Flavanoid consumption increased PAT hyperemic response Aversa et al (2008) 20 men with diabetes 4-wk Treatment with sildenafil or placebo Sildenafil increased PAT hyperemic response and FMD FMD, flow-mediated dilation; DM, diabetes mellitus; eNOS, endothelial nitric oxide synthase; L-NAME, L-nitro-arginine methyl ester.
obstructive sleep apnea, all similarly enhanced the PAT hyperemic response (Aversa et al. 2008 , Brauner et al. 2008 , Itzhaki et al. 2007 , Yeo et al. 2007 , 2008 Ongoing studies measuring endothelial function using PAT along with alternate methods will aid in determining the relative prognostic value of each vascular function test. Importantly, for any endothelial function test to assist in clinical risk stratification, the results need to provide incremental risk prediction and reclassification of risk over standard risk factors (Vasan 2006 , Pencina et al. 2008 . Longitudinal studies will evaluate whether certain groups of individuals will derive particular benefit from digital vascular testing, such as those at intermediate risk of cardiovascular events. In addition, it will be important to establish whether improvements in the PAT hyperemic response are associated with lower cardiovascular risk.
Summary and Conclusions
There is abundant evidence linking endothelial dysfunction to atherosclerosis and to an increased risk of cardiovascular events. Thus, a simple and accurate endothelial function test is an attractive, noninvasive addition to cardiovascular risk stratification tools. There is considerable interest in developing the test of digital vascular function using PAT as a method for evaluating endothelial function. The advantages of this technique include ease of administration and an automated analysis program that facilitate acquisition of reliable data. Recent studies demonstrate a modest relation between cardiovascular risk factors and digital vasodilator responses. Treatments thought to confer cardiovascular benefit are able to reverse endothelial dysfunction in the fingertip. However, much additional work is needed to define the clinical relevance of the PAT hyperemic response. Further studies evaluating the clinical and genetic determinants and the predictive value of digital vascular function are required to establish the role of PAT in clinical and research practice.
